Jacobio Pharmaceuticals Group Co Lt (1167)

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company’s drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor. In addition, the company is involved in the development of JAB-2485, an Aurora Kinase A inhibitor, under Phase I study indicated for the treatment of solid tumors; JAB-24114, a glutamine-utilizing enzyme inhibitor under IND study indicated for the treatment of solid tumors; and JAB-30355, an orally bioavailable small molecule activator under IND study for the treatment of patients with locally advanced or metastatic solid tumors. It has a license and collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.